
Anand Padmanabhan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8387336/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Persistence of Ad26.COV2.Sâ€associated vaccineâ€induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. American Journal of Hematology, 2022, 97, 519-526.	2.0	26
2	<scp>COVID</scp> â€19 <scp>mRNA</scp> â€1273 vaccine induces production of vaccineâ€induced immune thrombotic thrombocytopenia antibodies. American Journal of Hematology, 2022, 97, .	2.0	8
3	Chemoenzymatic Synthesis of Homogeneous Heparan Sulfate and Chondroitin Sulfate Chimeras. ACS Chemical Biology, 2022, 17, 1207-1214.	1.6	5
4	Risk of venous thromboembolism after COVIDâ€19 vaccination. Journal of Thrombosis and Haemostasis, 2022, 20, 1638-1644.	1.9	24
5	Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT. Blood Advances, 2022, 6, 5327-5329.	2.5	2
6	Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood, 2022, 140, 73-77.	0.6	32
7	Human papilloma virus vaccine and <scp>VITT</scp> antibody induction. American Journal of Hematology, 2022, 97, .	2.0	6
8	Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. Platelets, 2021, 32, 936-940.	1.1	42
9	A prospective, blinded study of a PF4-dependent assay for HIT diagnosis. Blood, 2021, 137, 1082-1089.	0.6	28
10	P-selectin expression assay in a repeatedly serotonin-release assay-negative patient with heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis, 2021, Publish Ahead of Print, 522-525.	0.5	1
11	A Thrombospondin-1 Release Assay (TRA) Coupled to PF4-Treated Cryopreserved Platelets for the Detection of Pathogenic HIT and VITT Antibodies. Blood, 2021, 138, 2130-2130.	0.6	0
12	Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications. Blood, 2021, 138, 292-292.	0.6	5
13	No Diagnostic Utility of Zero Heparin Control Buffer in Serotonin Release Assay: Findings from a Validation Study. Blood, 2021, 138, 3227-3227.	0.6	0
14	Diagnostic Utility of High Dose Heparin Confirmation Step in Heparin Induced Thrombocytopenia ELISA Assay. Blood, 2021, 138, 3228-3228.	0.6	0
15	Monoclonal and Oligoclonal Anti-PF4 Antibodies Mediate VITT. Blood, 2021, 138, 3220-3220.	0.6	2
16	Heparin-Induced Thrombocytopenia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 41, 141-152.	1.1	37
17	Update to the <scp>ASFA</scp> guidelines on the use of therapeutic apheresis in <scp>ANCAâ€associated</scp> vasculitis. Journal of Clinical Apheresis, 2020, 35, 493-499.	0.7	24
18	Enzymatic Synthesis of Chondroitin Sulfate E to Attenuate Bacteria Lipopolysaccharide-Induced Organ Damage. ACS Central Science, 2020, 6, 1199-1207.	5.3	23

Anand Padmanabhan

#	Article	IF	CITATIONS
19	Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation. Journal of Surgical Research, 2020, 255, 99-105.	0.8	1
20	Use of IV Immunoglobulin G in Heparin-Induced Thrombocytopenia Patients Is Not Associated With Increased Rates of Thrombosis. Chest, 2020, 158, 1172-1175.	0.4	11
21	Severe persistent heparin-induced thrombocytopenia in a renal transplant patient. Thrombosis Research, 2019, 183, 106-107.	0.8	4
22	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of Clinical Apheresis, 2019, 34, 171-354.	0.7	1,263
23	Use of intravenous immunoglobulin G to treat spontaneous heparinâ€induced thrombocytopenia. Transfusion, 2019, 59, 931-934.	0.8	39
24	Cellular collection by apheresis. Transfusion, 2018, 58, 598-604.	0.8	22
25	Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematology,the, 2018, 5, e220-e231.	2.2	76
26	Serotonin release assay (SRA)-negative HIT, a newly recognized entity: Implications for diagnosis and management. Thrombosis Research, 2018, 172, 169-171.	0.8	20
27	IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. Chest, 2017, 152, 478-485.	0.4	113
28	A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. Chest, 2017, 152, e77-e80.	0.4	20
29	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of Clinical Apheresis, 2016, 31, 149-338.	0.7	384
30	ä,ʿ床实践ä,治痗性å•采æœ⁻应用指å⊷——基于美国血浆置æ¢å¦ä¼šç¼–写委åʿ~ä	¹ ⁄4 šçኝ" å¾	[₽] ѐ¯ ⋠2Ţ•¥ï¼šç
31	A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. Chest, 2016, 150, 506-515.	0.4	80
32	Use of "Big Data" to Define Disease Burden, Complication Rates and Healthcare Costs in Patients with Heparin Induced Thrombocytopenia (HIT). Blood, 2016, 128, 418-418.	0.6	0

33	Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood, 2015, 125, 155-161.	0.6	79
34	Use of a dual lumen port for automated red cell exchange in adults with sickle cell disease. Journal of Clinical Apheresis, 2015, 30, 353-358.	0.7	27